Wire · opportunities
The cholesterol shot you couldn't afford is now a pill
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 17 July 2026 · Fusion42 review
Merck's Lipfendra, the first oral PCSK9 inhibitor, has received FDA approval for patients with persistent high cholesterol despite statin use, delivering 55-59% LDL reductions in trials. The pill addresses a decade-old access problem: injectable PCSK9 inhibitors from Amgen and others have been priced and restricted so heavily that most patients never received them.
This Wire brief sits within Fusion42's coverage of Digital Health.
◆ ◆ The Wire takeaway
If you're building patient access software or adherence tools for chronic disease, you've just gained 10 million potential users overnight: a new drug class that actually works just became affordable and easy to take. The problem that killed Amgen's injectable was distribution and cost friction - now Merck has solved it, and every hospital, payer, and primary care network needs to rebuild how they manage these patients.
◆ Coverage
1 source · 17 Jul 2026
◆ Related on Wire
◆ Topics